News

Announcement

Gemini Bio Announces the Acquisition of ORFLO Technologies

* ORFLO’s cell analysis offering to complement Gemini’s portfolio of cell culture reagents

WEST SACRAMENTO, CA, November 11, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading provider of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the acquisition of ORFLO Technologies (“ORFLO”), an innovative life sciences instrumentation company.

Announcement

Gemini Bio-Products Announces Partnership with FroggaBio

* FroggaBio to distribute Gemini’s media and sera products across Canada​

WEST SACRAMENTO, CA, October 1, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, is pleased to announce an exclusive distribution agreement for Canada with Toronto-based FroggaBio Inc. (“FroggaBio”). Starting today, customers in Canada will be able to purchase Gemini’s current and future products directly from FroggaBio.

Announcement

Gemini Bio-Products Breaks Ground on New Facility

* New state-of-the-art cGMP manufacturing facility to open in Q1 2020

WEST SACRAMENTO, CA, September 25th, 2019 – Gemini Bioproducts, LLC (“Gemini”), a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced that it has broken ground on a new, state-of-the-art manufacturing facility in West Sacramento, CA. The company expects to relocate operations to the new facility during the first quarter of 2020.

Announcement

Gemini Bio-Products to Distribute Nordmark products in the United States

* Gemini Bio-Products adds Nordmark’s Collagenase products to its portfolio

WEST SACRAMENTO, CA and HAMBURG, GERMANY, August 12, 2019 – Gemini Bioproducts, LLC (“Gemini”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced a distribution agreement with Nordmark Biochemicals, a division of Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”). Launching this week, customers in the United States can now purchase Nordmark’s line of collagenase and neutral protease products directly from Gemini.